Telix Pharmaceuticals (TLX) Expected to Announce Earnings on Friday

Telix Pharmaceuticals (NASDAQ:TLX) will likely be issuing its H2 2025 results after the market closes on Friday, February 20th. Analysts expect the company to announce earnings of $0.0493 per share and revenue of $421.5040 million for the quarter. Individuals may visit the the company’s upcoming H2 2025 earning results page for the latest details on the call scheduled for Thursday, February 19, 2026 at 5:30 PM ET.

Telix Pharmaceuticals Trading Down 0.2%

TLX stock opened at $6.41 on Thursday. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $30.36. The company has a fifty day simple moving average of $7.59 and a two-hundred day simple moving average of $9.33.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Wall Street Zen downgraded Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a report on Tuesday, January 27th. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Telix Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several hedge funds have recently bought and sold shares of TLX. Portland Investment Counsel Inc. increased its stake in Telix Pharmaceuticals by 108.0% in the fourth quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company’s stock worth $2,063,000 after purchasing an additional 138,200 shares during the period. Lazard Asset Management LLC grew its holdings in shares of Telix Pharmaceuticals by 118.6% in the fourth quarter. Lazard Asset Management LLC now owns 250,517 shares of the company’s stock worth $1,876,000 after purchasing an additional 135,893 shares during the last quarter. Millennium Management LLC purchased a new position in Telix Pharmaceuticals in the 3rd quarter worth about $1,883,000. Russell Investments Group Ltd. bought a new stake in Telix Pharmaceuticals during the 2nd quarter valued at about $975,000. Finally, Private Advisor Group LLC lifted its holdings in Telix Pharmaceuticals by 67.3% during the 3rd quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock valued at $403,000 after buying an additional 16,945 shares in the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.